undamentalytics Newsletter
Sign in

Neuropace Inc income statement

In fiscal 2025, Neuropace Inc reported revenue of $100.0m, up 25.1% on the year before, operating income of −$16.3m (a -16.3% margin) and net income of −$21.5m, or −$0.66 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue414546658010099
Cost of revenue11121317212320
Gross profit30333248597779
Research and development16182221242828
Selling, general and administrative2839515557——
Selling and marketing—————4747
General and administrative—————1919
Operating income−13−24−41−27−22−16−15
Interest expense11789976
Income tax—————0—
Net income−24−36−47−33−27−21−19
Diluted EPS−$117.85−$2.17−$1.91−$1.27−$0.93−$0.66−$0.57
Diluted shares (average)—17m25m26m29m33m34m
EBITDA−13−23−41−27−21−16−15

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CBLL vs NPCEDCTH vs NPCEIRMD vs NPCE

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Neuropace Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neuropace Inc.